Tilray Brands (NASDAQ:TLRY) Stock Price Up 8.1% on Analyst Upgrade

Tilray Brands, Inc. (NASDAQ:TLRY) rose 8.1% on Friday after TD Securities upgraded the stock to a strong-buy rating. The company traded as high as $4.56 and last traded at $4.54. 6,278,281 shares traded hands during mid-day trading, an increase of 46% from the average session volume of 4,310,874 shares. The stock had previously closed at $4.20.

TLRY has been the subject of a number of other reports. Weiss Ratings cut Tilray Brands from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Wednesday, May 13th. Wall Street Zen lowered Tilray Brands from a “hold” rating to a “sell” rating in a research report on Saturday. TD Cowen dropped their price target on shares of Tilray Brands from $7.00 to $5.00 and set a “buy” rating on the stock in a research note on Tuesday, July 14th. Roth Capital raised shares of Tilray Brands from a “neutral” rating to a “buy” rating and set a $10.00 price target for the company in a report on Thursday, April 2nd. Finally, ATB Cormark Capital Markets reduced their price objective on shares of Tilray Brands from $9.50 to $9.00 and set a “sector perform” rating for the company in a research report on Thursday, April 2nd. One research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Tilray Brands presently has an average rating of “Moderate Buy” and an average target price of $11.00.

Tilray Brands News Summary

Here are the key news stories impacting Tilray Brands this week:

• Positive Sentiment: Unusual options activity provided a bullish trading signal: investors purchased 23,521 TLRY call options, approximately 82% above the stock’s typical daily call volume. This suggests increased speculative interest in further gains.
• Positive Sentiment: Jefferies reiterated its Buy rating, saying Tilray is making progress in its transition toward a diversified consumer-products company. The firm’s view supports the potential for longer-term value from Tilray’s cannabis, beverage and other businesses. Tilray Brands seen creating long-term value through diversified platform, Jefferies says
• Neutral Sentiment: Southern Glazer’s Wine & Spirits completed its acquisition of substantially all of Eagle Rock Distributing’s Colorado assets. The transaction could be relevant to Tilray’s beverage-distribution strategy if it affects industry relationships, but the announcement did not directly identify Tilray or quantify an impact on its results. Southern Glazer’s Wine & Spirits Closes Acquisition of Eagle Rock Distributing Co.
• Negative Sentiment: Jefferies lowered its price target to $19 and reduced fiscal 2027 and 2028 EBITDA estimates after Tilray’s guidance for fiscal 2027 adjusted EBITDA of $68 million to $75 million came in below the roughly $84 million consensus estimate. The lower forecasts highlight continuing profitability concerns.
• Negative Sentiment: Tilray remains in a prolonged downtrend, having lost substantial value this year alongside other cannabis stocks. Its weak recent momentum and history of quarterly losses remain risks despite the current rebound. Tilray Brands stock continues its downward spiral

Institutional Trading of Tilray Brands

A number of institutional investors have recently made changes to their positions in the company. Hilton Head Capital Partners LLC acquired a new position in Tilray Brands in the 4th quarter valued at $38,000. Pictet Asset Management Holding SA boosted its stake in Tilray Brands by 38.9% during the 1st quarter. Pictet Asset Management Holding SA now owns 18,387 shares of the company’s stock worth $119,000 after purchasing an additional 5,145 shares during the last quarter. Schonfeld Strategic Advisors LLC boosted its stake in Tilray Brands by 4.5% during the 4th quarter. Schonfeld Strategic Advisors LLC now owns 144,358 shares of the company’s stock worth $1,304,000 after purchasing an additional 6,182 shares during the last quarter. Baader Bank Aktiengesellschaft boosted its stake in Tilray Brands by 17.7% during the 1st quarter. Baader Bank Aktiengesellschaft now owns 47,938 shares of the company’s stock worth $293,000 after purchasing an additional 7,226 shares during the last quarter. Finally, IFP Advisors Inc grew its holdings in shares of Tilray Brands by 14.3% during the fourth quarter. IFP Advisors Inc now owns 60,318 shares of the company’s stock worth $545,000 after buying an additional 7,541 shares in the last quarter. 9.35% of the stock is owned by institutional investors and hedge funds.

Tilray Brands Price Performance

The stock’s fifty day moving average price is $4.67 and its 200-day moving average price is $6.26. The firm has a market cap of $529.14 million, a PE ratio of -4.20 and a beta of 1.89. The company has a debt-to-equity ratio of 0.22, a current ratio of 2.21 and a quick ratio of 1.66.

Tilray Brands (NASDAQ:TLRY) last posted its quarterly earnings results on Tuesday, July 28th. The company reported ($0.43) earnings per share for the quarter, missing the consensus estimate of ($0.01) by ($0.42). The business had revenue of $281.71 million during the quarter, compared to analysts’ expectations of $246.30 million. Tilray Brands had a negative return on equity of 7.76% and a negative net margin of 13.11%. As a group, equities analysts expect that Tilray Brands, Inc. will post -0.34 EPS for the current fiscal year.

About Tilray Brands

Tilray Brands, Inc is a global cannabis-lifestyle and consumer packaged goods company engaged in the cultivation, production, distribution and sale of cannabis and cannabinoid-based products. The company develops and markets a diverse portfolio of branded products spanning medical cannabis, adult-use recreational products and wellness offerings. Through state-of-the-art cultivation facilities, research and development efforts, and quality control systems, Tilray Brands aims to deliver consistent, scalable products for a range of patient and consumer needs.

Tilray’s product lineup includes cannabis flower, pre-rolls, oils and tinctures, vapes, edibles and topicals, as well as hemp-derived cannabidiol (CBD) products.